Short-term results of early switch from Ranibizumab to Aflibercept in poor or non responder age related macular degeneration in clinical practice
Abstract Background To evaluate the change in best corrected visual acuity (VA) and central macular thickness (CMT) following treatment with intravitreal aflibercept (AFL) in patients poorly responders or non responders to ranibizumab (RBZ). Methods Charts of patients injected with RBZ from January...
Main Authors: | Luciana de Sá Quirino-Makarczyk, Maria de Fátima Sainz Ugarte, Bruna Viana Vieira, Sérgio Kniggendorf, Caio Vinicius Saito Regatieri |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-05-01
|
Series: | International Journal of Retina and Vitreous |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40942-020-00212-5 |
Similar Items
-
Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01) -
Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01) -
Comparison of the efficacy of aflibercept and ranibizumab after a 3-month loading dose in patients with diabetic macular edema
by: Murat Çakmaklıoğulları, et al.
Published: (2021-03-01) -
Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01) -
Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01)